These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6230227)

  • 1. In vitro emergence of Escherichia coli and Pseudomonas aeruginosa strains resistant to norfloxacin and nalidixic acid.
    Piffaretti JC; Demarta A; Leidi-Bulla L; Peduzzi R
    Eur J Clin Microbiol; 1983 Dec; 2(6):600-1. PubMed ID: 6230227
    [No Abstract]   [Full Text] [Related]  

  • 2. In-vitro activity of norfloxacin against Enterobacteriaceae and Pseudomonas aeruginosa.
    García-Rodríguez JA; Gómez-García AC; Rodrigo N
    J Antimicrob Chemother; 1984 Aug; 14(2):192-3. PubMed ID: 6238928
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid selection of organisms with increasing resistance on subinhibitory concentrations of norfloxacin in agar.
    Tenney JH; Maack RW; Chippendale GR
    Antimicrob Agents Chemother; 1983 Jan; 23(1):188-9. PubMed ID: 6219620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative activities of norfloxacin and fifteen other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa strains.
    Forward KR; Harding GK; Gray GJ; Urias BA; Ronald AR
    Antimicrob Agents Chemother; 1983 Oct; 24(4):602-4. PubMed ID: 6228193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa.
    Downs J; Andriole VT; Ryan JL
    Antimicrob Agents Chemother; 1982 Apr; 21(4):670-2. PubMed ID: 6211142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and oxolinic acid.
    Vuye A
    Arzneimittelforschung; 1983; 33(12):1623-7. PubMed ID: 6230083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Norfloxacin (MK-0366, AM-715): in vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing.
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1983 Jun; 1(2):165-72. PubMed ID: 6232084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membrane permeability of Pseudomonas aeruginosa to 4-quinolones.
    Kubesch P; Wehsling M; Tümmler B
    Zentralbl Bakteriol Mikrobiol Hyg A; 1987 Jun; 265(1-2):197-202. PubMed ID: 3118593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
    Guimaraes MA; Noone P
    J Antimicrob Chemother; 1986 Jan; 17(1):63-7. PubMed ID: 2936708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of norfloxacin against multi-resistant bacteria.
    Machka K; Vogelsang G
    Eur J Clin Microbiol; 1983 Jun; 2(3):270-1. PubMed ID: 6224686
    [No Abstract]   [Full Text] [Related]  

  • 11. [Comparison of the in vitro activity of 6 quinolones on Pseudomonas sp].
    Lesage D; Delisle-Mizon F; Vergez P; Daguet GL
    Pathol Biol (Paris); 1985 May; 33(5):412-5. PubMed ID: 3162141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of enoxacin compared with norfloxacin and amikacin.
    van der Auwera P; de Moor G; Lacroix G; Mambour A; Rossion N; Schuyteneer F
    Eur J Clin Microbiol; 1985 Feb; 4(1):55-8. PubMed ID: 3157568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro selection of Escherichia coli mutants with decreased susceptibility to norfloxacin.
    Forsgren A; Striby AC
    Scand J Infect Dis; 1988; 20(5):531-4. PubMed ID: 3065926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antibacterial activity of AM-715, a new nalidixic acid analog.
    Ito A; Hirai K; Inoue M; Koga H; Suzue S; Irikura T; Mitsuhashi S
    Antimicrob Agents Chemother; 1980 Feb; 17(2):103-8. PubMed ID: 6446258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].
    Croize J; Le Noc P; Bryskier A; Robert J
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):564-8. PubMed ID: 3937128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Influence of technical factors in the determination of minimal inhibitory concentration by microdilution].
    Forey F; Coulet M; Brun Y; Fleurette J
    Pathol Biol (Paris); 1985 May; 33(5):341-9. PubMed ID: 3162138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro sensitivity pattern of gram negative pathogens to nalidixic acid.
    Chitkara YK
    Indian J Pathol Bacteriol; 1969 Oct; 12(4):162-8. PubMed ID: 4990210
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative in vitro activities of norfloxacin (MK-0366) and six commonly used antimicrobial agents against 199 urinary isolates showing various degrees of antibiotic resistance.
    Corigliano BE; Appleman MD; Heseltine PN; Leedom JM
    Diagn Microbiol Infect Dis; 1984 Apr; 2(2):101-6. PubMed ID: 6232085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid.
    Teoh-Chan CH; Cowlishaw A; Eley A; Slater G; Greenwood D
    J Antimicrob Chemother; 1985 Jan; 15(1):45-52. PubMed ID: 3156113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The assessment of antimicrobial activity in an in-vitro model of the treatment of bacterial cystitis.
    Greenwood D
    J Antimicrob Chemother; 1984 May; 13 Suppl B():43-8. PubMed ID: 6234274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.